Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038
Peer-Reviewed Publication Highlights the Critical Role of Inflammation Regulator NFkB as a Target for Ref-1 inhibition Using APX3330 and APX Pipeline Compounds
Read more at globenewswire.com